Navigation Links
Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma
Date:12/7/2009

iminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Nycomed, Merck Serono, and MedImmune.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include the efficacy, safety and intended utilization of blinatumomab, the dosing schedule designed to reduce adverse events of blinatumomab, the mode of action of BiTE antibodies, and the conduct, timing and results of future clinical trials of blinatumomab. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product can
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
4. Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Randy Olver Named Emdat CEO, Will Lead Next Phase of Growth for Medical Transcription Solutions Provider
7. NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC)
8. AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
9. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
10. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
11. AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Lecrae is ... been noted everywhere from Rolling Stone and The New York Times to Billboard Magazine ... life experiences are one of the many reasons why so many people are taking ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... critical in order to enhance successful student outcomes. According to Dr. Theo ... capacity to adapt.” Teachers must be able to show “all kinds of behavior ...
(Date:6/30/2015)... ... 2015 , ... Americans report feeling more stressed than ever before. There’s even ... stressed out people right over the edge. , Almost half of Americans report ... night. Sleeping pills now lead the list of the most prescribed medications, despite reported ...
(Date:6/30/2015)... ON (PRWEB) , ... June 30, 2015 , ... Curly ... – 14, the largest beauty event in the US, featuring products from all over ... Curl Keeper™ Collection. The Collection is a line of hair styling products focused entirely ...
(Date:6/29/2015)... ... June 30, 2015 , ... Sublime Beauty NATURALS® introduces its new ... The oil, ideal for natural skincare and even culinary uses, was especially designed for ... most people desire, and Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic ...
Breaking Medicine News(10 mins):Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 2Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 3Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 2Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 3Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2
... in a workshop to discuss the various surgical techniques ... West have different approaches to cosmetic surgery. The medicine ... and burns than on aesthetic surgery," Anil Chadha, a ... Aesthetica 2006. ,He added: "But of late, priorities ...
... in Shanghai but one of them is still critical, a ... twin girls remains in critical condition and doctors are trying ... after they were successfully separated in a hospital in Shanghai ... and Chen Jingni were separated during an operation lasting nearly ...
... discovered something new about exotic particles called solitons.Since ... carry an electrical charge when traveling through certain ... solitons have intricate internal structures. ,Scientists may ... particles to work in molecular electronics and artificial ...
... and Human Services, on behalf of the Indian Health ... to collaborate in seeking ways to reduce the burden ... Alaska Native communities. ,The public signing will incorporate ... color guard. It will be conducted at 1:30 p.m. ...
... a wonder hormone which is discovered around 1994 which has ... appetite, burns calories// and performs other crucial physiological activities. ... action through which Leptin carries out these metabolic activities were ... College of Medicine of Yeshiva University have identifies the mode ...
... in a global ,program to catalogue human mutations in their ... ,For a sample of the expected rewards, ... at the division of human genetics at the University of ... family who suffered from a heredity eye disease, which led ...
Cached Medicine News:Health News:Solitons Could Power Molecular Electronics, Artificial Muscles 2Health News:Solitons Could Power Molecular Electronics, Artificial Muscles 3Health News:Mayo Clinic and Indian Health Service Form Clinical Practice Collaboration 2Health News:How Does Leptin Work? 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 3
(Date:6/29/2015)... June 29, 2015  Daktari Diagnostics was honored at the ... in the Service of Society Award. IEEE President and CEO, ... L. Shoop presented the award to Principal Scientist ... was held Saturday, June 20, 2015, at the historic Waldorf ... "I have spent more than 3 years ...
(Date:6/29/2015)... ZIONA, Israel , June 29, 2015 ... TASE: BVXV) today announced positive preliminary results from its ... for a universal influenza vaccine. In this trial, M-001 ... 50 to 65, followed by an administration of the ... M-001 was found to be safe and well tolerated ...
(Date:6/29/2015)... , June 29, 2015 Regeneron Pharmaceuticals, ... the Proceedings of the National Academy of ... that the Company,s proprietary VelociGene ® and ... and preclinical validation of potential candidates that could ... Middle East Respiratory Syndrome (MERS). This involved the ...
Breaking Medicine Technology:Daktari Honored with IEEE Spectrum Award 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 2Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 4Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 5
... MedVantx, Inc., the company that created first ever controlled access ... Inc. Magazine has rated the company as one of the ... year in a row, MedVantx has made the list.  In ... thirteenth overall. The Inc. 500/5000 list is the ...
... 2011 CORPAK MedSystems, Inc., a leading ... enteral feeding and bedside-technology markets, today announced the appointment ... officer. Mr. Blair brings 40 years ... recently as the chairman and chief executive officer of ...
Cached Medicine Technology:MedVantx Honored by Inc. 500/5000 Three Years in a Row 2CORPAK MedSystems Names Jeffrey Blair Chief Executive Officer 2CORPAK MedSystems Names Jeffrey Blair Chief Executive Officer 3